C.E.S. TABLET
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
23-09-2020
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
CONJUGATED ESTROGENS
제공처:
BAUSCH HEALTH, CANADA INC.
ATC 코드:
G03CA57
INN (International Name):
CONJUGATED ESTROGENS
복용량:
0.625MG
약제 형태:
TABLET
구성:
CONJUGATED ESTROGENS 0.625MG
관리 경로:
ORAL
패키지 단위:
100/1000
처방전 유형:
Prescription
치료 영역:
ESTROGENS
제품 요약:
Active ingredient group (AIG) number: 0106442006; AHFS:
승인 상태:
APPROVED
승인 날짜:
2020-09-23
제품 특성 요약
PRODUCT MONOGRAPH
PR
C.E.S.
Conjugated Estrogens Tablets, CSD
0.625 mg
ESTROGEN
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 23, 2020
Laval, Quebec
H7L 4A8
Control No.: 242944
_Pr_
_C.E.S._
_®_
_ Product Monograph Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................24
DETAIL
전체 문서 읽기
